Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.
This Code system is referenced in the content logical definition of the following value sets:
Properties
Code URL Type Description
Specializes Coding The child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric.
Generalizes Coding Inverse of Specializes. Only included as a derived relationship.
internalId http://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-id code The internal identifier for the concept in the HL7 Access database repository.
notSelectable http://hl7.org/fhir/concept-properties#notSelectable boolean Indicates that the code is abstract - only intended to be used as a selector for other concepts
status http://hl7.org/fhir/concept-properties#status code Designation of a concept's state. Normally is not populated unless the state is retired.
This code system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution defines the following codes:
Lvl Code Display Definition internalId Not Selectable status
1 _ActSubstanceAdminSubstitutionCode ActSubstanceAdminSubstitutionCode **Description:** Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. 21284 true active
2 E equivalent **Description:** Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. 23107 active
3 EC equivalent composition **Description:**
Substitution occurred or is permitted with another product that is a:
* pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
* pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration
*Examples:*
* *Pharmaceutical alternative:* Erythromycin Ethylsuccinate for Erythromycin Stearate
* *Pharmaceutical equivalent:* Lisonpril for Zestril 23108 active
4 BC brand composition **Description:**
Substitution occurred or is permitted between equivalent Brands but not Generics
*Examples:*
* Zestril for Prinivil
* Coumadin for Jantoven 23109 active
4 G generic composition **Description:** Substitution occurred or is permitted between equivalent Generics but not Brands
*Examples:*
* Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) 16623 active
3 TE therapeutic alternative **Description:** Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.
*Examples:*
* ranitidine for Tagamet 16624 active
4 TB therapeutic brand **Description:** Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics
>
*Examples:*
* Zantac for Tagamet 23105 active
4 TG therapeutic generic **Description:** Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands
>
*Examples:*
* Ranitidine for cimetidine 23106 active
2 F formulary **Description:** This substitution was performed or is permitted based on formulary guidelines. 16625 active
2 N none No substitution occurred or is permitted. 16622 active